Polo-like kinases in AML

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

(2012) B. Valsasina et al.   MOLECULAR CANCER THERAPEUTICS

Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo

(2011) Juping Yuan et al.   AMERICAN JOURNAL OF PATHOLOGY

Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions

(2011) Leonidas Benetatos et al.   ANNALS OF HEMATOLOGY

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

(2011) B. Lowenberg et al.   BLOOD

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

(2011) Monika Raab et al.   Nature Communications

Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns

(2010) V. Gupta et al.   BLOOD

High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia

(2010) Antonio R. Lucena-Araujo et al.   LEUKEMIA RESEARCH

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML

(2010) Y. Wang et al.   SCIENCE

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis

(2009) Wolfgang Reindl et al.   CHEMBIOCHEM

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

(2009) T Ikezoe et al.   LEUKEMIA

Polo-like kinases: conservation and divergence in their functions and regulation

(2009) Vincent Archambault et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Clinical Experience with Aurora Kinase Inhibitors: A Review

(2009) D. S. Boss et al.   ONCOLOGIST

Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay

(2009) Jung-Eun Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions

(2008) Wolfgang Reindl et al.   CHEMISTRY & BIOLOGY

Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia

(2008) Christine Didier et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition

(2008) Nobumoto Watanabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Distinct microRNA expression profiles in acute myeloid leukemia with common translocations

(2008) Z. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA